1. Home
  2. FMY vs SPRO Comparison

FMY vs SPRO Comparison

Compare FMY & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FMY
  • SPRO
  • Stock Information
  • Founded
  • FMY 2005
  • SPRO 2013
  • Country
  • FMY United States
  • SPRO United States
  • Employees
  • FMY N/A
  • SPRO N/A
  • Industry
  • FMY Finance/Investors Services
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • FMY Finance
  • SPRO Health Care
  • Exchange
  • FMY Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • FMY 49.6M
  • SPRO 40.5M
  • IPO Year
  • FMY N/A
  • SPRO 2017
  • Fundamental
  • Price
  • FMY $12.05
  • SPRO $0.69
  • Analyst Decision
  • FMY
  • SPRO Buy
  • Analyst Count
  • FMY 0
  • SPRO 4
  • Target Price
  • FMY N/A
  • SPRO $5.00
  • AVG Volume (30 Days)
  • FMY 10.1K
  • SPRO 111.2K
  • Earning Date
  • FMY 01-01-0001
  • SPRO 05-13-2025
  • Dividend Yield
  • FMY 6.98%
  • SPRO N/A
  • EPS Growth
  • FMY N/A
  • SPRO N/A
  • EPS
  • FMY N/A
  • SPRO N/A
  • Revenue
  • FMY N/A
  • SPRO $47,977,000.00
  • Revenue This Year
  • FMY N/A
  • SPRO N/A
  • Revenue Next Year
  • FMY N/A
  • SPRO N/A
  • P/E Ratio
  • FMY N/A
  • SPRO N/A
  • Revenue Growth
  • FMY N/A
  • SPRO N/A
  • 52 Week Low
  • FMY $10.71
  • SPRO $0.51
  • 52 Week High
  • FMY $12.17
  • SPRO $1.72
  • Technical
  • Relative Strength Index (RSI)
  • FMY 50.15
  • SPRO 53.47
  • Support Level
  • FMY $12.00
  • SPRO $0.57
  • Resistance Level
  • FMY $12.11
  • SPRO $0.64
  • Average True Range (ATR)
  • FMY 0.12
  • SPRO 0.04
  • MACD
  • FMY 0.00
  • SPRO 0.00
  • Stochastic Oscillator
  • FMY 47.25
  • SPRO 67.04

About FMY First Trust Motgage Income Fund of Beneficial Interest

First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: